24(8): p
Sergi B, Yuksel-Catal N, Ozcan SC, Syed H, Duvvuri U, Kiselyov K, et al
Of these, 597 were current users and 224 were former users
Ozempic (semaglutide) is a GLP-1 receptor agonist administered subcutaneously for type 2 diabetes management Lumps commonly form due to injection technique errors including inadequate site rotation, injecting too rapidly, or removing the needle too soon after injection Normal lumps are firm, mobile, mildly tender, and gradually reduce in size without warmth, spreading redness, or systemic symptoms Seek medical attention for progressive enlargement, increasing pain, signs of infection (warmth, discharge, fever), or difficulty breathing Prevention requires proper technique including systematic site rotation (23 cm from previous sites), keeping the needle in place for at least 6 seconds post-injection, and never reusing needles Lipohypertrophy (persistent rubbery lumps from repeated injections in the same area) impairs medication absorption and requires strict site avoidance Table of Contents Why Lumps Form After Ozempic Injections Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist administered subcutaneously for the management of type 2 diabetes mellitus
Most patients have 3 sessions per year for ongoing maintenance
Related peptide guides Ready when you are BPC-157 The body protection compound for accelerated healing From $169/mo compounded by a licensed 503A pharmacy, dispensed only after provider review
